Related Experiment Video
Updated: Jun 27, 2026
11:13
Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
Dehydrocorydaline Exerts Anti-Pancreatic Cancer Effects Through the PI3K/Akt/mTOR Pathway
Qingmeng Yu1, Ruiding Li2, Zhengyu Li2
1School of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Pharmaceuticals (Basel, Switzerland)
|June 26, 2026
Summary
Dehydrocorydaline, from Corydalis yanhusuo, shows anti-pancreatic cancer effects by promoting cell death and inhibiting growth. Its mechanism involves suppressing HSP90α and ERBB2, impacting key signaling pathways.
Area of Science:
- Pharmacology
- Oncology
- Molecular Biology
Background:
- Pancreatic cancer remains a significant health challenge with limited effective treatments.
- Corydalis yanhusuo W.T. Wang is a traditional herb with potential therapeutic compounds.
- Dehydrocorydaline is identified as a key active component of Corydalis yanhusuo.
Purpose of the Study:
- To investigate the pharmacological effects of dehydrocorydaline on pancreatic cancer cells.
- To elucidate the underlying molecular mechanisms of dehydrocorydaline's action.
- To evaluate dehydrocorydaline as a potential therapeutic agent for pancreatic cancer.
Main Methods:
- Cell viability and proliferation assessed via MTT and colony formation assays.
- Apoptosis, migration, and invasion evaluated using flow cytometry, scratch wound, and Transwell assays.
- Molecular mechanisms explored through bioinformatics analysis and Western blot.
Main Results:
- Dehydrocorydaline significantly inhibited proliferation, migration, and invasion of BxPC-3 pancreatic cancer cells.
- Dehydrocorydaline induced apoptosis in pancreatic cancer cells.
- Mechanistically, dehydrocorydaline suppressed Heat Shock Protein 90 alpha (HSP90α) expression and induced Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) degradation, impacting STAT3 and PI3K/Akt/mTOR pathways.
Conclusions:
- Dehydrocorydaline exhibits potent anti-pancreatic cancer activity.
- The anti-cancer effects are mediated through the inhibition of HSP90α and ERBB2, leading to the suppression of critical signaling pathways.
- Dehydrocorydaline represents a promising candidate for further development as a pancreatic cancer therapeutic.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.